RAS Mutations Can Predict Resistance To Vectibix, FOLFOX Combination Treatment
Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months
ODAC Votes 13:0 For Approving Perjeta
Early Treatment with CMX001 Can Help Prevent CMV Infection
Researchers Identify Mutation Linked to Inherited Risk of ALL
Drug Combination Can Block Proteins Preventing Cell Death In Acute Lymphoblastic Leukemia
Avoiding the Hippocampus During Whole-Brain Radiotherapy Can Preserve Memory Function
Stereotactic Radiosurgery Improves Survival Without Whole-Brain Radiotherapy
Long-term Hormonal Therapy Adds No Additional Benefits
NCI CTEP Approved Trials For the Month of September
FDA Approves Generic Version Of Capecitabine for Metastatic Colorectal and Breast Cancer
Trending Stories
- The faces of RIF: Staff members of NCI’s dissolved communications team gather for a farewell group photo
- NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science - George Sigounas named the first-ever chief science advisor at NCI
- In The Headlines: Increasing incidence of early-onset cancer is “a paradigm shift oncology isn’t quite prepared for”
- Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State
- Loss of Y chromosome “cripples” immune cells, University of Arizona researcher finds
Cells with LOY may induce LOY in otherwise healthy cells—a finding that could explain variability in CAR T-cell therapy response
